following statement was released by the rating agency) CHICAGO, May 18 (Fitch) Fitch Ratings has downgraded Abbott Laboratories ' (Abbott) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook
April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.
April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion...
April 22 (Reuters) - Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.
April 22 (Reuters) - Abbott Laboratories ' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions.
Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense
example, Novartis has an estimated 60% market share, yet surgical sales make up only about 6% of total company sales. At Abbott ABT and Valeant, the next-largest players, ophthalmology surgical products account for 5%-7% of total company sales
in the global home healthcare market that have been profiled in the report include 3M Health Care, Bayer AG, Abbott Laboratories , Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services, Inc
in ophthalmology, since Valeant will face a much more concentrated market and larger competitors, such as Novartis NVS , Abbott ABT , and Johnson & Johnson JNJ , but we still believe there will still be attractive opportunities for Valeant. The market is
methodology. If we go back to several years ago when we first started this, firms that ranked very well like [TICKER:ABT] Abbott ( ABT ) and [TICKER:NVS] Novartis (NVS), following two years of their high rankings, they posted 40% gains. A lot of this